Skip to main content
BIO·ATLASby Bayes Pharma.ai
Search
AccountStart evaluation
AI drug discovery models/Antibodies & Biologics/BigHat Biosciences — Milliner
model-family passport · Review date not recorded

BigHat Biosciences — Milliner

Closing the ML–wet-lab loop for antibody engineering.

1/7Evidence fields documented
60-SECOND EVALUATION VIEW

What should a scientist know before using BigHat Biosciences — Milliner?

UnresolvedEvidence direction is incomplete or not yet resolved
Best suited forGeneration · Optimization
Evidence supportsPrimary links may be present, but BioAtlas does not claim a review date without a record-level timestamp.
Evidence does not establishUniversal superiority, therapeutic success, clinical utility or regulatory acceptance.
Major limitationIndependent reproducibility is limited by proprietary access.
CompareAdd to evaluationView evidence
Current registry recordVersion history not yet curated1 recorded release · Review date not recorded. A newer version is not assumed to be universally better.

What it is

BigHat pairs machine learning with a high-speed in-house synthesis-and-measurement lab (its Milliner platform) to engineer antibodies with better affinity, stability and developability. Co-founder Mark DePristo previously led deep-learning genomics at Google (DeepVariant).

Evidence trail

BioAtlas keeps the path from source to decision visible. A connection records provenance; it does not imply that evidence is sufficient for every context.

Sources1 connectedPrimary resources and normalized claims
Claims0 normalizedNo normalized claim yet
EntityBigHat Biosciences — Millinermodel-family · Version history not yet curated
ReviewReview date not recordedReview date not claimed
ConclusionContext requiredAdd to an evaluation before operational use

Model passport

Entity typemodel-family
OrganizationBigHat Biosciences
Model family introducedNot normalized
AccessProprietary
Commercial useVendor terms
DeploymentVendor managed
ComputeManaged platform or GPU
Domainsantibody
Biology → representation → computation → evidence

How BigHat Biosciences — Milliner represents biology

model-familyantibody

Category is navigation. These fields describe the model-specific computational transformation and deliberately override broad category defaults.

1 · Biological inputs
Antigen, sequence or desired properties
2 · Input representation
Sequence and/or antigen geometry
3 · Internal representation
Antibody representation
4 · Architecture
Antibody model
5 · Learning objective
Antibody prediction / design
6 · Output representation
SequenceStructureScores

Biological scale

Modalities & tasks

AntibodyProteinGenerationOptimizationPrediction

Registry, claims and frontier intelligence

Versioned registry

Version history not yet curated

1 version record · release year not yet normalized. Model-family identity remains separate from capability and access changes.

Explore version lineage →
Benchmark claim ledger

0 normalized claims

No task, dataset, split and metric claim has been normalized for this record yet.

Open claim intelligence →

Inputs and outputs

Inputs

Antigen, sequence or desired properties

Outputs

Antibody candidatesAffinity or developability estimates

Scientific and technical profile

Scientific principles

Active learningDesign–build–test–learn loopsMulti-property optimization

Technology

ML sequence modelsRapid wet-lab characterizationBayesian optimization
Ideas before algorithms

Scientific lineage

Explore all foundations

These are transparent concept matches—not claims that one scientist alone caused this model. Each connection is based on the model’s recorded domain, scientific principles, technical terms or an explicit lineage link.

Biologics & genome engineering

Hybridoma production of monoclonal antibodies

Georges J. F. Köhler & César Milstein

Therapeutic antibodies, diagnostic antibodies and antibody discovery platforms became scalable and reproducible.

Matched concepts: antibody, antigen
Biologics & genome engineering

Somatic gene rearrangement generates antibody diversity

Susumu Tonegawa

Antibody language models and repertoire design operate on the sequence space created by V(D)J recombination and somatic diversification.

Matched concepts: antibody, sequence
Biologics & genome engineering

Phage display and selection of binding proteins

George P. Smith & Sir Gregory P. Winter

Display-based selection created an experimental search engine for protein binders and remains a core validation partner for computational antibody design.

Matched concepts: antibody, affinity
Physical chemistry

Gibbs free energy and chemical equilibrium

J. Willard Gibbs

Binding affinity, conformational stability, solvation, phase behavior and free-energy calculations all inherit this framework.

Matched concepts: stability
Molecular recognition

Cooperative ligand binding

Archibald V. Hill

Dose–response curves, receptor occupancy, multisite binding and systems pharmacology still use Hill-type models.

Matched concepts: affinity
Structural biology

Anfinsen’s dogma—the thermodynamic hypothesis

Christian B. Anfinsen

Protein structure prediction, inverse folding and generative protein design all assume that sequence strongly constrains structure and function.

Matched concepts: sequence

Evaluation evidence

Dataset or evaluationNot yet curated
Task or metricNot yet extracted
Evidence statusNo task-specific benchmark record curated
Open source ↗

BioAtlas has not yet extracted a structured benchmark claim for this record.

Known limitations

  • Independent reproducibility is limited by proprietary access.
  • A structured benchmark claim has not yet been extracted for this record.
  • Outputs require task-specific scientific and experimental validation.

Milestones

Not normalized

Co-founder built Google's DeepVariant.

Evidence

Runs an integrated ML + wet-lab platform.